Thus, any possibility of systemic therapy would need to first define an AMPK inhibitor of high specificity followed by testing in animal models to determine if a therapeutic window exists in which GVHD is inhibited but AMPK-related side effects can be minimized. This evidence concerns the gene PRKAA1 and graft versus host disease.